Autor(es):
Salazar, Ivan L. ; Lourenço, Ana S. T. ; Manadas, Bruno ; Baldeiras, Inês ; Ferreira, Cláudia ; Teixeira, Anabela Claro ; Mendes, Vera M. ; Novo, Ana Margarida ; Machado, Rita ; Batista, Sónia ; Macário, Maria do Carmo ; Grãos, Mário ; Sousa, Lívia ; Saraiva, Maria João ; Pais, Alberto A. C. C. ; Duarte, Carlos B.
Data: 2022
Identificador Persistente: https://hdl.handle.net/10316/99647
Origem: Estudo Geral - Universidade de Coimbra
Assunto(s): Biomarkers; Cerebrospinal fluid (CSF); Multiple sclerosis; Transthyretin (TTR)
Descrição
Multiple sclerosis is an inflammatory and degenerative disease of the central nervous system (CNS) characterized by demyelination and concomitant axonal loss. The lack of a single specific test, and the similarity to other inflammatory diseases of the central nervous system, makes it difficult to have a clear diagnosis of multiple sclerosis. Therefore, laboratory tests that allows a clear and definite diagnosis, as well as to predict the different clinical courses of the disease are of utmost importance. Herein, we compared the cerebrospinal fluid (CSF) proteome of patients with multiple sclerosis (in the relapse-remitting phase of the disease) and other diseases of the CNS (inflammatory and non-inflammatory) aiming at identifying reliable biomarkers of multiple sclerosis.
This work was fnanced by the National Multiple Sclerosis Society (USA) (RG-1601-07502), Biogen and by grants from the Portuguese Science and Technology Foundation (FCT), the European Regional Development Fund (ERDF)
